All || Biopharma || Diagnostics and Life Science Tools || Medical Device || Healthcare IT || Healthcare Services || Exited

3SBio

Fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China

IPO in May 2015 (HKSE: 1530)

AADI Bioscience

Clinical stage biopharmaceutical company developing a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin

Albireo Pharma

Clinical stage biopharma company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other adult liver diseases and disorders

(NASDAQ:ALBO)

Alpine Immune Sciences

Biotech company developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases

(NASDAQ:ALPN)

AnHeart Therapeutics

Clinical-stage biopharmaceutical company based in China focused on the acquisition, development and commercialization of oncology products

Apexigen

Clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology

Arcus Biosciences

Clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies

IPO in March 2018 (NASDAQ:RCUS)

Ariagen

Biotech company founded by Decheng Capital to develop a novel class of small molecules as cancer immunotherapies

Ark Biosciences

Ark Biosciences is a biotech startup company focusing on innovative drug discovery and development, especially in the respiratory virus field, for world-wide markets

ARMO Biosciences

Late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors

Acquired by Eli Lilly in May 2018

BeyondSpring

Clinical-stage biopharmaceutical company developing plinabulin, an anti-cancer agent

(NASDAQ:BYSI)

Bioheng

Biotech company based in China developing universal CAR-T products

Checkmate Pharmaceuticals

Clinical stage biopharma company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies

IPO in August 2020 (NASDAQ: CMPI)

EpimAb Biotherapeutics

Biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform

Everest Medicines

Biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia

IPO in October 2020 (HKSE: 1952)

GRIT Biotechnology

Biotech company developing tumor infiltration lymphocytes immunotherapy for solid tumors

 

Hummingbird Bioscience

Biotech company, with facilities in Singapore and Silicon Valley, focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics

 

IMPACT Therapeutics

Clinical stage biopharmaceutical company focusing on discovery and development of best-in-class anti-cancer drugs targeting a poly (ADP-ribose) polymerase (PARP)

KeChow Pharma

Clinical-stage biotech based in China focused on developing small molecules for clinically validated oncology targets

Kind Pharmaceutical

Clinical stage biopharmaceutical company based in China focusing on discovery and development of best-in-class anemia drugs

LYNK Pharmaceuticals

Preclinical stage biotech comapny focused on researching and developing JAK family small molecules

Scynexis

Biotech company developing innovative therapies for difficult-to-treat and often life-threatening infections

(NASDAQ:SCYX)

Terns Pharmaceuticals

Clinical stage biopharma company based in Shanghai and Silicon Valley developing oral, small molecule drugs for nonalcoholic steatohepatitis (NASH), a liver disease

VelosBio

Biopharma company focused on developing an antibody-drug conjugate of cirmtuzumab, a ROR1 antibody

Acquired by Merck in November 2020

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.